These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35159053)

  • 21. Apyrase protects against allergic airway inflammation by decreasing the chemotactic migration of dendritic cells in mice.
    Li P; Cao J; Chen Y; Wang W; Yang J
    Int J Mol Med; 2014 Jul; 34(1):269-75. PubMed ID: 24804736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
    Geraghty NJ; Watson D; Sluyter R
    Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toll-Like Receptor-Mediated Activation of CD39 Internalization in BMDCs Leads to Extracellular ATP Accumulation and Facilitates P2X7 Receptor Activation.
    Zhao R; Qiao J; Zhang X; Zhao Y; Meng X; Sun D; Peng X
    Front Immunol; 2019; 10():2524. PubMed ID: 31736956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attenuated allergic airway inflammation in Cd39 null mice.
    Idzko M; K Ayata C; Müller T; Dürk T; Grimm M; Baudiß K; Vieira RP; Cicko S; Boehlke C; Zech A; Sorichter S; Pelletier J; Sévigny J; Robson SC
    Allergy; 2013 Apr; 68(4):472-80. PubMed ID: 23452076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting CD39 in cancer.
    Moesta AK; Li XY; Smyth MJ
    Nat Rev Immunol; 2020 Dec; 20(12):739-755. PubMed ID: 32728220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of vascular expression of nucleoside triphosphate diphosphohydrolase-1/CD39 in hypertension.
    Roy C; Tabiasco J; Caillon A; Delneste Y; Merot J; Favre J; Guihot AL; Martin L; Nascimento DC; Ryffel B; Robson SC; Sévigny J; Henrion D; Kauffenstein G
    Purinergic Signal; 2018 Mar; 14(1):73-82. PubMed ID: 29236227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2.
    Jeon HM; Sohn YW; Oh SY; Kim SH; Beck S; Kim S; Kim H
    Cancer Res; 2011 May; 71(9):3410-21. PubMed ID: 21531766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor-infiltrating CD39
    Hu G; Wu P; Cheng P; Zhang Z; Wang Z; Yu X; Shao X; Wu D; Ye J; Zhang T; Wang X; Qiu F; Yan J; Huang J
    Oncoimmunology; 2017; 6(2):e1277305. PubMed ID: 28344891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
    Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
    Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
    Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
    Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purinergic signaling during intestinal inflammation.
    Longhi MS; Moss A; Jiang ZG; Robson SC
    J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
    Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
    Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenovirus infection promotes the formation of glioma stem cells from glioblastoma cells through the TLR9/NEAT1/STAT3 pathway.
    Zang J; Zheng MH; Cao XL; Zhang YZ; Zhang YF; Gao XY; Cao Y; Shi M; Han H; Liang L
    Cell Commun Signal; 2020 Aug; 18(1):135. PubMed ID: 32843056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
    Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
    Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma.
    Ma Q; Long W; Xing C; Chu J; Luo M; Wang HY; Liu Q; Wang RF
    Front Immunol; 2018; 9():2924. PubMed ID: 30619286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
    Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
    Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia.
    Perry C; Hazan-Halevy I; Kay S; Cipok M; Grisaru D; Deutsch V; Polliack A; Naparstek E; Herishanu Y
    Ann Hematol; 2012 Aug; 91(8):1271-9. PubMed ID: 22349724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of Metastases via Myeloid CD39 and NK Cell Effector Function.
    Yan J; Li XY; Roman Aguilera A; Xiao C; Jacoberger-Foissac C; Nowlan B; Robson SC; Beers C; Moesta AK; Geetha N; Teng MWL; Smyth MJ
    Cancer Immunol Res; 2020 Mar; 8(3):356-367. PubMed ID: 31992567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
    Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
    Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.